Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
Conditions: Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcin oma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8 Interventions: Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Drug: Sorafenib Sponsors: University of California, San Francisco; Bayer; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Urology & Nephrology